Myriad Genetics, Inc. (MYGN) focuses on developing and marketing products for the healthcare industry. While its Predictive Medicine Products help assess risks for various cancers, its Therapeutic Products focus on treating patients with Alzheimer's disease, cancer, obesity, thrombosis, and HIV. In fiscal year 2007 (ended June 2007), diagnostic products such as BRACAnalysis (for testing breast cancer), COLARIS (for colon and uterine cancer), MELARIS (for skin cancer), and COLARIS AP (for adenomatus polyposis) contributed the bulk of the company's revenue of $157.1 million. The therapeutic products are under various stages of clinical development, and the company is developing these products either on its own, or in association with other corporate partners including Eli Lilly, Bayer Corporation, Schering-Plough, and Novartis. Notable collaborations in the Predictive Medicine division are with Abbott Labs, DuPont, Pfizer, and Roche.
Based in Salt Lake City, UT, the company employs more than 650 people.(Read more at Wikinvest )